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Mutations in oncogenes and tumour suppressor genes contribute to
the transformation of tumour cells. Frequently, these mutations are
associated with allelic loss in the corresponding other parental
region. Since allelic loss is readily detected such analyses can
serve to point towards candidate genes residing in the affected
regions. Recently, the INI1 (SMARCB1/hSNF5) gene, localizing
to chromosome 22, was found to be mutated in paediatric malig-
nant rhabdoid tumours (Versteege et al, 1998; Rousseau-Merck et al,
1999) and with a lower frequency in CNS tumours (Sevenet et al,
1999). INI1 therefore is an interesting candidate gene for tumours
with allelic loss on chromosome 22 (LOH 22) seen in many
different brain tumours. These include meningiomas (Dumanski
et al, 1990), schwannomas (Seizinger et al, 1986), astrocytomas
(James et al, 1988), ependymomas (James et al, 1990; Ebert et al,
1999) and glioblastomas (James et al, 1988). However, a major
proportion of LOH 22 is associated with mutations in the NF2
gene on 22q12. This has been shown most evidently for menin-
giomas and schwannomas (Jacoby et al, 1994; Ruttledge et al,
1994a; Wellenreuther et al, 1995). On the other hand, the
frequency of LOH 22 exceeds that of NF2 mutations and deletion
mapping has revealed interstitial deletions not including the NF2
locus in some meningiomas (Ruttledge et al, 1994b). Therefore,
additional meningioma genes have been postulated. An interesting
candidate forwarded was b-adaptin, showing a reduced expression
in meningiomas (Peyrard et al, 1994). However, a mutational
analysis failed to detect mutations of b-adaptin leaving the rele-
vance of its reduced expression unresolved (Peyrard et al, 1996). 
In order to evaluate the role of the INI1 gene in the pathogenesis
of meningiomas we analysed a series of 21 tumours with LOH 22
but without recognizable NF2 mutations and a second unselected
series of 105 meningiomas. 
MATERIAL AND METHODS 
Tumour specimens, histopathology and control DNA 
Native tumour specimens and corresponding blood samples were
obtained from patients treated at the University Hospital Bonn
between 1990 and 1998. All tumours were classified according to
the WHO guidelines (Kleihues and WK, 2000). The tumour speci-
mens were examined microscopically prior to phenolic DNA
extraction to exclude contamination by adjacent tissue. The
analyses were performed on an initial series of 21 meningioma
samples with LOH 22 but without NF2 gene mutations and on a
series of 105 meningiomas without prior knowledge of either LOH
22 or mutations of NF2. All patients have consented to molecular
analysis of their respective meningioma and constitutional DNA. 
SSCP analysis and direct sequencing 
For analysis of the INI1 gene a set of previously published primers
was employed (Versteege et al, 1998). The sequence for the newly
devised overlapping PCR product of exon 9 was ex9f 5¢-GAGA-
GAAGGCTGGGTCTGAC and ex9r 5¢-GTGCTGATGGGCTG-
GTTACC. PCR was performed in a final volume of 10 ml
containing 10 ng of DNA, 50 mM KCl, 20 mM Tris-HCl (pH 8.4),
200 mM of each dNTP, 0.1% gelatine, 10 pmol of each primer, 1.0
to 2.0 mM MgCl2 and 0.25 U Taq polymerase (AmpliTaq® DNA
Polymerase, Perkin Elmer, USA). Initial denaturation at 94˚C
for 3 min was followed by 30 cycles on an automated thermal
cycler (Biometra UNO Thermoblock, Göttingen, Germany). These
included denaturation at 94˚C for 40 s, annealing at temperatures
ranging from 50–62˚C depending on the primer pair for 40 s, and
extension at 72˚C for 40 s. A final extension step at 72˚C for 
10 min was added. Single strand conformation polymorphism
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(BlueSeq 400, Boehringer Ingelheim, Germany) using 8%, 10%,
12% and 14% acrylamide gels. Electrophoresis was run at 2 W to
6 W and variable temperatures for 15 h. Silver staining of the gels
was performed as previously described (von Deimling et al, 1993).
Aberrantly migrating SSCP bands were excised and the DNA was
extracted followed by reamplification with the same set of primers
and sequencing on a semiautomatic sequencer (Applied Bio-
systems, model 377) using the BigDye Terminator Cycle
Sequencing kit (Applied Biosystems). Each amplicon was
sequenced bidirectionally. 
RESULTS AND DISCUSSION 
4 of 126 meningiomas (3%) carried an identical somatic mutation
in exon 9 of the INI1 gene. Corresponding DNAs from peripheral
blood cells exhibited wild type status in all 4 patients (Figure 1,
upper panel). The alteration was characterized by an G to A transi-
tion in the nucleotide 1130 of the coding sequence resulting in an
missense mutation of Arg to His in codon 377 (Figure 1, lower
panel). This nucleotide exchange was not observed in DNA
samples from 104 healthy individuals, from 200 other intracranial
brain tumours (A. v. D. unpublished data) and has not been reported
previously. In order to exclude accidental contamination of
template DNA with a potentially single mutated DNA amplicon,
two independent strategies were employed. The DNA extraction
was repeated from frozen tissue of these 4 patients. Subsequent
SSCP analysis of exon 9 of INI1 provided identical results to those
from our first round of experiments. Amplification of the polymor-
phic microsatellite D1S1608 using these DNAs as template yielded
different alleles thereby confirming independent origin of the
tissues. In addition, a novel primer pair was synthesized extending
beyond the initially amplified fragment. PCR with these oligonu-
cleotides yielded aberrantly migrating signals in the tumour DNA
from the same patients. This PCR product could not have been
amplified from a partly overlapping contaminating fragment. Thus,
our results suggest a mutational hotspot at nucleotide 1130 of INI1
affected in approximately 3% of meningioma patients. One muta-
tion occurred in our first series with 21 meningiomas exhibiting
LOH 22 but without detectable NF2 mutations. Three additional
mutations were detected in our second series containing 105
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Figure 1 Upper panel: SSCP of exon 9 of the INI1 gene in human
meningiomas. Aberrantly migrating products are seen in exon 9 amplicons
from meningioma DNA but not in amplicons derived from DNA of
corresponding blood samples. C–= unaffected control, M =meningioma, 
B = peripheral blood leukocytes, C+ = positive control. Lower panel:
Sequencing revealed a G to A transition in the nucleotide 1130 of the coding
sequence resulting in an missense mutation of Arg to His in codon 377 in all
four instances 
Table 1 Sequence polymorphisms in the INI1 gene 
Allele Alleles in controls Allele in patients Position Nucleotide Amino acid 
n f n f 
A1 78 – 250 0.992 exon 4 406 T 136 Ser 
A2 0 – 2 0.008 406 C 136 Pro 
B1 152 – 251 0.996 intron 5 628 + 13 c 
B2 0 – 1 0.004 628 + 13 t
C1 84 0.609 154 0.611 intron 5 629 – 58 c 
C2 54 0.391 98 0.389 629 – 58 a 
D1 113 0.819 206 0.817 intron 5 629 – 62 a 
629 - (125 to 130) ccccc 
D2 25 0.181 46 0.183 629 – 62 g 
629 - (125 to 130) del c 
E1 188 0.783 223 0.885 exon 7 897 G 299 Ser 
E2 52 0.217 29 0.115 897 A 299 Ser 
F1 170 0.817 194 0.770 intron 8 1119 – 41 g 
F2 38 0.183 58 0.230 1119 – 41a 
Allele frequencies, nucleotides affected and amino acid exchange are given for the six observed polymorphisms. meningiomas. Three of the four meningiomas contained different
NF2 mutations each presumably resulting in premature chain
termination. Two of those exhibited LOH 22 and one was not infor-
mative for the markers tested. The meningioma apparently wild
type for NF2 exhibited LOH 22. These findings do not support the
concept of INI1 mutations serving as an alternate mechanism to
NF2 mutations in the pathogenesis of meningiomas. In contrast, the
data rather indicate, that silencing of INI1 may co-operate with
impairment of NF2 function. Histopathological evaluation of those
4 meningiomas with INI1 mutations revealed two meningiomas of
the transitional and one meningioma each of the fibroblastic and
meningotheliomatous subtype. A recent study analysed a series of
41 meningiomas for mutations of INI1 (Bruder et al, 1999). While
this study examined 90% of the open reading frame of INI1, exons
1 and 9 were not included in this analyses, providing an explanation
for missing the present observation. 
We detected 4 novel polymorphisms in coding and intronic
sequences of INI1. In addition we saw two previously described
polymorphism in exon 7 and intron 8 (Bruder et al, 1999; Mine
et al, 1999). A known variant in exon 6 was either not repre-
sented in our series or missed by the SSCP assay (Bruder et al,
1999). The variants were designated A–F with two alleles each.
The C2 variant always combined a nucleotide exchange 58 base
pairs upstream of exon 6 with a deletion of a single cytosine 100
base pairs upstream of exon 6. The allele frequencies in menin-
gioma patients and healthy control individuals are given in Table
1. With the exception of allele E, the incidences of the respective
alleles were identical in meningioma patients and in healthy
control patients suggesting no modifying role of these INI1 vari-
ants in the pathogenesis of meningiomas. The frequency of E2 in
our meningioma series was similar to the one described previ-
ously (Bruder et al, 1999), however, in healthy controls allele E2
was observed more frequently (P < 0.01). This difference should
be interpreted with caution but warrants examination of an inde-
pendent series. 
INI1 is part of the SWI/SNF complex participating in tran-
scriptional regulation by remodelling chromatin in an ATP
dependent manner. INI1 contains three regions highly conserved
among related proteins. These consist of two imperfect repeats,
Rpt1 and Rpt2 and an c-terminal putative coiled coil domain
(Morozov et al, 1998). Rpt1 is required for interaction with c-
myc (Cheng et al, 1999). The c-terminal coiled coil domain is
likely to be involved in protein-protein interactions yet to be
specified. The somatic Arg to His mutations in codon 377 falls
within the highly conserved coiled coil domain, and may there-
fore interfere with normal protein–protein interactions. However,
no functional data on the effect of the Arg to His mutation in
codon 377 are available. 
In conclusion, we detected a hotspot mutation in the INI1 gene in
3% of the present series of meningiomas. This observation suggest,
that INI1 is a second tumour suppressor gene on chromosome 22 that
may be involved in the pathogenesis of meningiomas. 
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